Dalmia Fresenius Medicals Profile
Key Indicators
- Authorised Capital ₹ 7.50 Cr
as on 19-12-2024
- Paid Up Capital ₹ 6.65 Cr
as on 19-12-2024
- Company Age 36 Year, 1 Day
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 3.08 Cr
as on 19-12-2024
- Revenue %
(FY 2017)
- Profit -150.40%
(FY 2017)
- Ebitda -150.40%
(FY 2017)
- Net Worth -0.18%
(FY 2017)
- Total Assets %
(FY 2017)
About Dalmia Fresenius Medicals
The Company is engaged in the Industrial Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 7.50 Cr and a paid-up capital of Rs 6.65 Cr.
The company currently has active open charges totaling ₹3.08 Cr.
Arvind Agrawal, Anoop Patwal, and Narender Pal serve as directors at the Company.
- CIN/LLPIN
U29297DL1989PLC034700
- Company No.
034700
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Jan 1989
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Dalmia Fresenius Medicals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anoop Patwal  | Director | 30-Jul-2013 | Current |
| Arvind Agrawal | Director | 20-Dec-2013 | Current |
| Narender Pal | Director | 01-Dec-2012 | Current |
Financial Performance of Dalmia Fresenius Medicals.
Dalmia Fresenius Medicals Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 150.4% decrease in profit. The company's net worth dipped by a decrease of 0.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dalmia Fresenius Medicals?
In 2017, Dalmia Fresenius Medicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
India Tele-Comp LimitedActive 38 years 6 monthsArvind Agrawal, Anoop Patwal and 1 more are mutual person
- Tijil Consultancy Services Private LimitedActive 14 years 5 months
Arvind Agrawal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Central Bank Of India Creation Date: 15 Sep 2001 | ₹1.09 Cr | Open |
Central Bank Of India Creation Date: 25 Sep 1991 | ₹1.09 Cr | Open |
International Asset Reconstruction Company Private Limited Creation Date: 08 May 1990 | ₹9.00 M | Open |
How Many Employees Work at Dalmia Fresenius Medicals?
Unlock and access historical data on people associated with Dalmia Fresenius Medicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dalmia Fresenius Medicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dalmia Fresenius Medicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
